Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Tolerability, Biological Effects and Pharmacokinetics of BIIL 284 BS in Healthy Males

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BIIL 284 oral solution
Drug: BIIL 284 wetability improved formulation (WIF) tablets

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 95

Registration Number: NCT02265302

Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]talsaclidine, iv
Drug: [14C]talsaclidine, oral

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6

Registration Number: NCT02264054

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Talsaclidine
Drug: Placebo

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02264067

Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cilobradine, high, film-coated tablets
Drug: Moxifloxacin, film-coated tablets
Drug: Cilobradine, low, film-coated tablets
Drug: Placebo, film-coated tablets

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 125

Registration Number: NCT02264015

Influence of Telmisartan and Lacidipine, Combined or Alone, on QT Interval in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan low
Drug: Placebo
Drug: Telmisartan high
Drug: Lacidipine high
Drug: Lacidipine low

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 149

Registration Number: NCT02264158

Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL in 12 Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-DK-AH 269 CL, drinking solution
Drug: [14C]-DK-AH 269 CL, solution for infusion

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264028

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) Administered Orally to Healthy Adult Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: WAL2014
Drug: Placebo

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264080

Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cilobradine high dose 1
Drug: Placebo
Drug: Cilobradine low dose 1
Drug: Cilobradine high dose 2
Drug: Cilobradine low dose 2
Drug: Cilobradine medium dose
Drug: Metoprolol succinate tablets

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 119

Registration Number: NCT02264002

Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tamsulosin HCl
Drug: Ketoconazole

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02264171

Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lefradafiban tablet
Drug: Pantoprazole tablet
Device: Lefradafiban double chamber sachet

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264119

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy